Pozen rated at outperform by RBC

RBC Capital Markets analyst Ken Trbovich rated Pozen, Inc. at outperform, speculative risk, on news of an agreement between AstraZeneca and the company to develop an arthritis pain reliever. AstraZeneca will pay Pozen an upfront fee totaling $40 million with additional milestone payments of $160 million and possible sales performance milestone payments totaling $175 million. Shares of the Chapel Hill, N.C.-based pharmaceutical company were up $2.95, or 39.39%, at $10.44, on volume of 8,771,630 shares versus the three-month running average of 1,526,480 shares. (Nasdaq: POZN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.